

Available online at www.sciencedirect.com

ScienceDirect

Mendeleev Commun., 2017, 27, 283-284

Mendeleev Communications


2-Aminopyrimidines in just two steps from ketones, acetylenes and guanidine *via* β , γ -enones

Elena Yu. Schmidt, Inna V. Tatarinova, Elena V. Ivanova and Boris A. Trofimov*

A. E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 664033 Irkutsk, Russian Federation. Fax: +7 3952 419 346; e-mail: boris_trofimov@irioch.irk.ru

DOI: 10.1016/j.mencom.2017.05.022


Available β , γ -enones, the products of nucleophilic addition of ketones to phenylacetylene, react with guanidine in the KOH/DMSO system at 70 °C to give 2-aminopyrimidines in up to 72% yield.



The aminopyrimidine scaffold is frequently met in pharmaceuticals including anti-atherosclerotic Aronixil[®], anti-histaminic Thonzylamine[®], anti-psoriatic Enazadrem[®], antianxielytic Buspirone[®], and many others.¹ The aminopyrimidine derivatives inhibit protein kinases and are one of the most important discoveries in aminopyrimidine chemistry.² Therefore, the search for a new facile and more direct access to substituted aminopyrimidines that would allow one to extend their structural diversity and hence the potential of their application, is an important challenge of modern organic synthesis.

Readily accessible (*via* nucleophilic addition of ketones to acetylenes, Scheme 1)³ diverse β , γ -enones are flexible synthons for the construction of valuable carbo- and heterocyclic compounds.⁴

Here, a one-pot synthesis of 2-aminopyrimidines 2a-c and 3a,b from ketones 1 and guanidinium nitrate is described (Scheme 2).[†] Two series of aminopyrimidines can be obtained, namely 4-benzyl substituted 2a-c and unsubstituted at the 4-position 3a,b that result






 † The IR spectra were recorded on a Bruker IFS25 spectrophotometer. The NMR spectra were recorded on Bruker DPX-400 and AV-400 spectrometers (400.1 MHz for 1 H, 100.6 MHz for 13 C and 40.5 MHz for 15 N) in CDCl₃. The assignment of signals was made using COSY, NOESY, 1 H- 13 C HSQC, 1 H- 13 C HMBC, and 2D 1 H- 15 N HMBC experiments. The formation of toluene was detected by GC analysis of reaction mixture using the standards [Agilent 6890N, HP-5MS column (0.25 mm \times 30 m \times \times 0.25 µm), carrier gas – helium, constant flow].

Aminopyrimidines **2**, **3** (typical procedure). A mixture of ketone **1** (5 mmol), KOH \cdot 0.5H₂O (6 mmol, 390 mg) and guanidinium nitrate (6.0 mmol, 733 mg) in DMSO (10 ml) was stirred at 70 °C for 0.5 h (for **1b,c**), 3.0 h (for **1a,d**) and 4.0 h (for **1e**). Then more KOH \cdot 0.5H₂O (5 mmol, 325 mg) was added and the mixture was stirred at 70 °C for 30 min. After cooling to room temperature, the mixture was diluted with H₂O (15 ml), neutralized with NH₄Cl and extracted with CHCl₃ (4×10 ml). The organic extract was washed with H₂O (3×5 ml) and dried (MgSO₄). The solvent was evaporated *in vacuo* and the residue was purified by column chromatography (Al₂O₃, eluent C₆H₆-Et₂O, 1:0 \rightarrow 10:1).

from elimination of toluene. Products of type **3** are formed when $R^2 \neq H$ in starting ketones **1**.


Obviously, the assembly of 2-aminopyrimidines 2 and 3 involves the following key transformations (Scheme 3). Ketones 1 react with guanidine in DMSO giving adducts A, which undergo ring



Scheme 2 Reagents and conditions: i, (H₂N)₂C=NH·HNO₃, KOH/DMSO; ii, KOH, 70 °C.

4-Benzyl-6-(tert-butyl)pyrimidin-2-amine **2a**: yield 808 mg (67%); cream oil. ¹H NMR, δ : 1.20 (s, 9 H, 3 Me), 3.87 (s, 2 H, CH_2 Ph), 5.02 (br. s, 2 H, NH₂), 6.44 (s, 1H, H⁵), 7.20–7.22 (m, 3 H, *o*,*p*-H), 7.27–7.30 (m, 2 H, *m*-H). ¹³C NMR, δ : 29.5 (Me), 37.3 (*C*Me₃), 44.4 (*C*H₂Ph), 106.4 (C⁵), 126.7 (*p*-C), 128.7 (2*m*-C), 129.3 (2*o*-C), 138.5 (*i*-C), 163.0 (C⁴), 170.1 (C²), 179.6 (C⁶). ¹⁵N NMR, δ : –138.8 (N³), –143.0 (N⁴), –306.3 (NH₂). IR (film, ν /cm⁻¹): 3487, 3398, 3325, 3317, 3062, 3028, 2962, 2928, 2870, 1953, 1885, 1811, 1613, 1577, 1552, 1487, 1448, 1396, 1359, 1237, 1201, 1174, 1155, 1076, 1029, 965, 926, 853, 804, 758, 703, 574, 552, 524. Found (%): C, 74.60; H, 7.98; N, 17.36. Calc. for C₁₅H₁₉N₃ (%): C, 74.65; H, 7.94; N, 17.41.

4-Benzyl-6-phenylpyrimidin-2-amine **2b**: yield 588 mg (45%); cream solid; mp 90–94 °C. ¹H NMR, δ : 3.90 (s, 2H, CH₂Ph), 5.41 (br. s, 2H, NH₂), 6.75 (s, 1H, H⁵), 7.17–7.27 (m, 5H, Ph), 7.28–7.35 (m, 3H, Ph), 7.78–7.88 (m, 2H, Ph). ¹³C NMR, δ : 44.3 (CH₂Ph), 107.1 (C⁵), 126.8 (=CH), 127.1 (=CH), 128.7 (=CH), 129.3 (=CH), 130.4 (=CH), 137.6 (=C), 138.0 (=C), 163.4 (C⁴), 165.8 (C⁶), 170.9 (C²). ¹⁵N NMR, δ : –136.8 (N³), –145.2 (N¹), –304.2 (NH₂). IR (film, ν /cm⁻¹): 3477, 3317, 3183, 3085, 3062, 3029, 2924, 2852, 1954, 1891, 1811, 1626, 1600, 1573, 1548, 1495, 1454, 1359, 1238, 1181, 1073, 1030, 1002, 909, 872, 844, 769, 733, 699, 655, 605, 532. Found (%): C, 78.31; H, 5.65; N, 15.95. Calc. for C₁₇H₁₅N₃ (%): C, 78.13; H, 5.79; N, 16.08.





closure to dihydropyrimidines **B**. The latter further aromatize *via* the two different routes. When $R^2 = H$, intermediates **B** expectedly (due to tendency of dihydroheterocyclic systems to aromatization, sometimes spontaneous) lose hydride anion to afford aminopyrimidines **2** along with dihydrogen and hydroxide anion. When $R^2 \neq H$, the elimination of toluene (detected by GC) from the dihydropyrimidine ring takes place to deliver benzyl-free aminopyrimidines **3** (see Scheme 3).

Control experiment in argon atmosphere showed that air oxygen was not the reason for aromatization of dihydropyrimidine intermediates **B**. Also, DMSO (*cf.* ref. 5) and nitrate ion were not the oxidants inasmuch as Me₂S was not detected (GC-MS) and replacement of guanidinium nitrate for its chloride brought about the same results. Most probably, one should take into consideration the dehydrogenation with the hydride ion transfer commonly occurring in strongly basic media (*cf.* ref. 6).

The common aromatization (dehydrogenation) is probably initiated by the abstraction of a proton from the 5-position that is accompanied by hydride-ion loss from the 4-position, facilitated by electrophilic assistance by the proton of water (see Scheme 3). The unusual aromatization (with elimination of toluene) is likely

4-Benzyl-6-(2-naphthyl)pyrimidin-2-amine **2c**: yield 871 mg (56%); white solid; mp 163–168 °C. ¹H NMR, δ : 4.00 (s, 2 H, *CH*₂Ph), 5.12 (br. s, 2 H, NH₂), 6.98 (s, 1H, H⁵), 7.20–7.38 (m, 5 H, Ph), 7.47–7.52 (m, 2 H, naphthyl), 7.82–7.92 (m, 3 H, naphthyl), 7.98–8.01 (m, 1H, naphthyl), 8.43 (s, 1H, naphthyl). ¹³C NMR, δ : 44.4 (*CH*₂Ph), 107.3 (C⁵), 124.2 (=CH), 126.5 (*p*-C), 126.8 (=CH), 127.0 (=CH), 127.1 (=CH), 127.7 (=CH), 128.5 (=CH), 128.8 (m-C), 129.0 (=CH), 129.3 (*o*-C), 133.3 (=C), 134.5 (=C), 134.8 (C⁷), 138.1 (*i*-C), 163.5 (C⁴), 165.7 (C⁶), 171.0 (C²). ¹⁵N NMR, δ : –136.6 (N³), –144.7 (N¹), –304.9 (NH₂). IR (film, *v*/cm⁻¹): 3476, 3313, 3184, 3061, 3027, 2923, 2860, 1918, 1629, 1568, 1551, 1503, 1454, 1366, 1233, 1178, 1144, 1076, 1027, 904, 852, 808, 752, 704, 568, 471. Found (%): C, 80.81; H, 5.55; N, 13.58. Calc. for C₂₁H₁₇N₃ (%): C, 81.00; H, 5.50; N, 13.49.

5,6,7,8-*Tetrahydroquinazolin-2-amine* **3a**: yield 537 mg (72%); white solid; mp 182–187 °C. ¹H NMR, δ : 1.75–1.77 (m, 2 H, 6-CH₂), 1.81–1.83 (m, 2 H, 7-CH₂), 2.55–2.58 (m, 2 H, 5-CH₂), 2.64–2.67 (m, 2 H, 8-CH₂), 4.94 (br. s, 2 H, NH₂), 7.95 (s, 1H, H⁴). ¹³C NMR, δ : 21.9 (C⁷), 22.1 (C⁶), 24.4 (C⁵), 31.3 (C⁸), 119.4 (C¹⁰), 157.7 (C⁴), 160.8 (C²), 166.3 (C⁹). IR (film, ν /cm⁻¹): 3299, 3157, 2991, 2927, 2849, 2838, 2762, 1656, 1650, 1632, 1595, 1572, 1557, 1536, 1510, 1503, 1478, 1454, 1441, 1422, 1416, 1346, 1335, 1314, 1276, 1244, 1213, 1180, 1154, 1143, 1107, 1097, 1077, 1065, 959, 944, 937, 858, 822, 788, 772, 762, 749, 727, 670, 665, 637, 593, 558, 505. Found (%): C, 64.32; H, 7.49; N, 28.10. Calc. for C₈H₁₁N₃ (%): C, 64.40; H, 7.43; N, 28.16.

5-*Methyl*-6-*phenylpyrimidin*-2-*amine* **3b**: yield 629 mg (68%); cream solid; mp 122–128 °C. ¹H NMR, δ: 2.16 (s, 3 H, Me), 5.16 (br. s, 2 H, NH₂), 7.35–7.47 (m, 3H, *m,p*-H), 7.49–7.55 (m, 2H, *o*-H), 8.17 (s, 1H, H⁴). ¹³C NMR, δ: 15.9 (Me), 117.4 (C⁵), 128.3 (*m*-C), 128.4 (*o*-C), 128.9 (*p*-C), 138.6 (*i*-C), 159.9 (C⁴), 161.7 (C²), 166.2 (C⁶). ¹⁵N NMR, δ: –133.8 (N¹), –135.9 (N³), –307.1 (NH₂). IR (film, *v*/cm⁻¹): 3344, 3295, 3163, 2936, 1633, 1593, 1573, 1543, 1477, 1441, 1409, 1385, 1289, 1202, 1180, 1143, 1078, 989, 913, 806, 777, 745, 710, 639, 595, 563. Found (%): C, 71.41; H, 5.93; N, 22.61. Calc. for C₁₁H₁₁N₃ (%): C, 71.33; H, 5.99; N, 22.69.

to result from the steric hindrance at the 5-position by substituent R^2 (which prevents the hydroxide ion attack) and from a lower acidity of the C(5)–H bond due to the donor effect of this alkyl (alkylene) moiety. This promotes elimination of the benzyl substituent as a stabilized carbanionic species with simultaneous proton transfer from the 4-position.

In conclusion, a straightforward synthesis of 2-aminopyrimidines, pharmaceutically appealing precursors, has been developed *via* reaction between β , γ -enones (readily available from the basecatalyzed addition of ketones to acetylenes) and guanidine. This approach features the following synthetic advantages: inexpensive transition metal-free catalyst (KOH), environmentally benign, nontoxic solvent (DMSO), diverse structural variation in the products and operationally simple protocol.

Online Supplementary Materials

Supplementary data associated with this article can be found in the online version at doi: 10.1016/j.mencom.2017.05.022.

References

- (a) M. A. El-Hashash, M. R. Mahhmoud and S. A. Madboli, *Indian J. Chem., Sect. B*, 1993, **32**, 449; (b) D. Wustrow, H. Akunne, T. Belliotti, M. D. Davis, T. Heffner, S. Kesten, L. Meltzer, T. Pugsley and L. Wise, *Eur. Neuropsychopharm.*, 1996, **6**, S4; (c) G. S. Rashinkar, S. B. Pore, K. B. Mote and R. S. Salunkhe, *Indian J. Chem., Sect. B*, 2009, **48**, 606.
- 2 (a) K. L. Sayle, J. Bentley, F. T. Boyle, A. H. Calvert, Y. Cheng, N. J. Curtin, J. A. Endicott, B. T. Golding, I. R. Hardcastle, P. Jewbury, V. Mesguiche, D. R. Newell, M. E. M. Noble, R. J. Parsons, D. J. Pratt, L. Z. Wang and R. J. Griffin, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3079; (b) T. V. Hughes, S. L. Emanuel, A. K. Beck, S. K. Wetter, P. J. Connolly, P. Karnachi, M. Reuman, J. Seraj, A. R. Fuentes-Pesquera, R. H. Gruninger, S. A. Middleton, R. Lin, J. M. Davis and D. F. C. Moffat, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 3266; (c) E. V. Koroleva, Zh. I. Ignatovich, Yu. V. Sinyutich and K. N. Gusak, *Russ. J. Org. Chem.*, 2016, **52**, 139 (*Zh. Org. Khim.*, 2016, **52**, 159).
- 3 B. A. Trofimov, E. Yu. Schmidt, N. V. Zorina, E. V. Ivanova and I. A. Ushakov, J. Org. Chem., 2012, 77, 6880.
- 4 (a) E. Yu. Schmidt, I. V. Tatarinova, E. V. Ivanova, N. V. Zorina, I. A. Ushakov and B. A. Trofimov, Org. Lett., 2013, **15**, 104; (b) E. Yu. Schmidt, N. V. Zorina, E. V. Ivanova, I. V. Tatarinova, I. A. Ushakov, A. I. Mikhaleva and B. A. Trofimov, Mendeleev Commun., 2013, **23**, 340; (c) Y.-C. Wang, H.-S. Wang, G.-B. Huang, F.-P. Huang, K. Hu and Y.-M. Pan, Tetrahedron, 2014, **70**, 1621; (d) S. Undeela, J. P. Ramchandra and R. S. Menon, Tetrahedron Lett., 2014, **55**, 5667; (e) E. Yu. Schmidt, E. V. Ivanova, N. V. Semenova, I. V. Tatarinova, I. A. Ushakov and B. A. Trofimov, Mendeleev Commun., 2015, **25**, 131; (f) L. Ouyang, C. Qi, H. He, Y. Peng, W. Xiong, Y. Ren and H. Jiang, J. Org. Chem., 2016, **81**, 912; (g) E. Yu. Schmidt, I. V. Tatarinova, I. A. Ushakov and B. A. Trofimov, Mendeleev Commun., 2016, **26**, 378.
- 5 Y. Siddaraju and K. R. Prabhu, J. Org. Chem., 2016, 81, 7838.
- 6 (a) J. Dumas and J. S. Stass, *Justus Liebigs Ann. Chem.*, 1840, **35**, 129;
 (b) R. A. Dytham and B. C. L. Weedon, *Tetrahedron*, 1960, **8**, 246;
 (c) H. Machemer, *Angew. Chem.*, 1952, **64**, 213.

Received: 5th October 2016; Com. 16/5065